Company intelligence / Profile preview
Meridigen Biotech Co., Ltd.
Zhubei, Hsinchu County, Taiwanmeridigen.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Meridigen’s lead program UMC119‑06 has reached Phase 2 for COPD and Phase 1 for frailty syndrome. UMC119‑01 has completed IND review by US FDA and Taiwan FDA for bronchopulmonary dysplasia. The company’s pipeline includes preclinical to early clinical-stage assets targeting pulmonary and neurological diseases with hUC-MSC therapies. Early results focus on safety evaluation in first-in-human studies
- Therapeutic areas
- OtherPulmonologyCardiovascularNeurology
- Modalities
- Mesenchymal stem cells (MSCs)specifically umbilical cord-derived mesenchymal stem cells (hUC-MSCs)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Academic collaborations with Industrial Technology Research Institute Biomedical Research CentreNational Chiao Tung UniversityTaipei Medical UniversitySouthern Taiwan University of Science & TechnologyNational Dong Hwa University; hospital partnerships with Cardinal Tien HospitalE-Da Hospital & Chi Mei Hospital
Beyond the preview
Go deeper on Meridigen Biotech Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Meridigen Biotech Co., Ltd..